Johnson & Johnson stock price forecast for 2040: Pipeline depth and MedTech scale push toward $600

Traders Union
All News
Financial News
Johnson & Johnson stock price outlook

Highlights

Price has drifted down to the $235 area after failing to hold above the $248-$251 zone.
RSI is at 35.32, which is weak but not deeply oversold.
$234 is an important level worth watching on the downside.

One thing worth sitting with for a moment is the valuation re-rating that has quietly happened here. J&J's market cap was $348 billion at the end of 2024 and is now $566 billion, yet the trailing P/E has fallen from 24.09x to 21.34x over the same period. The 20-period EMA at $237.18 and the 50-period EMA at $239.16 are both above the current price, and the stock needs to get back through those before anything constructive can develop.

Johnson & Johnson price dynamics (December 2025 to March 2026). Source: TradingView.

Pharmaceutical pipeline depth can reshape J&J's earnings through 2040

There is a version of J&J that most long-term models underestimate, and it starts with recognizing that the consumer health spinoff into Kenvue was not just a restructuring move; it was a deliberate shift toward higher-margin pharmaceutical and MedTech revenue. The forward P/E of 20.41 does not feel expensive once you factor in that the business sitting underneath it is materially different from what it was three years ago. Enterprise Value/EBITDA at 14.49 is reasonable for what is effectively a pure-play healthcare compounder with $594 billion in enterprise value.

MedTech does not generate the same headlines, but it carries the business through periods when pharmaceutical revenue is lumpy. Surgical robotics, orthopedic reconstruction, cardiovascular devices, and vision care all benefit from the same demographic tailwind: aging populations in developed markets spending more on elective and necessary procedures. That division provides a floor for earnings, making the compounding story more durable over a 14-year horizon.

Key levels to watch as consolidation develops

Importantly, the long-term price dynamics largely depend on J&J reaching around $350 by the end of 2030 and $470 by the end of 2035. Compounding at around 8% annually from there makes $600 by 2040 a natural destination rather than a stretch. A faster path exists if two or three pipeline approvals land ahead of schedule through the late 2020s and MedTech margins expand faster than expected as the robotics platform scales, in which case the $600 level arrives closer to 2037 or 2038.

In the previous analysis of Johnson & Johnson, it was noted that the $248 to $252 zone would act as a ceiling and that a pullback was likely if the stock failed to clear that range on volume. What followed confirmed that call, with price retreating steadily from that exact area through the back half of February and into March.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.